Presentations
2011
Ackaert O., Rijn-Bikker P.v., Snelder N., Hest R.v., Ploeger B., Monfrans G.v., Koopmans R. and Mathot R., Population modeling of blood pressure: assessing clinically important factors for cardiovascular diseases. PAGE.(2011)...[more]
2011
Snelder N., Ploeger B.A., Danhof M., Stanski D.R., Rigel D., Webb R., Feldman D. and Luttringer O., Quantitative understanding of drug effects on the interrelationship between mean arterial blood pressure, cardiac output and...[more]
2011
Maanen E.V., Challenges in Non-Clinical Assessment of Antisense Oligonucleotides: Modelling Perspectives. Oral presentation at the AAPS National Biotechnology...[more]
2010
Stringer F., Jongh J.d, Ploeger B., Scott G., Urquart R. and Danhof M., Clinical impact of genetic polymorphisms observed in the pharmacokinetics of the novel PPAR agonist, Sipoglitazar. Noordwijkerhout.(2010).[more]
2010
Snelder N., Ploeger B., Danhof M., Stanski D., Rigel D., Webb R., Feldman D. and Luttringer O., Drug effects on the Cardiovascular system – development of a mechanism-based pharmacodynamic model to improve translational drug...[more]
2010
Jongh J.d. and Ploeger B., A population PD model for effects of the cytostatic drugs Irinotecan and Temozolomide on Rh18 rabdomyosarcoma xenografts in mice. Noordwijkerhout.(2010).[more]
2010
Maanen E. v., Brady K., Steeg T.v. and Graaf P.v.d., A novel integrated RNAi/viral dynamics systems pharmacology model to predict clinical efficacy of viral vector delivery of siRNA for the treatment of HCV....[more]
2010
Diack C., Ackaert O., Ploeger B., Graaf P.v.d., Gurrell R., Ivarsson M. and Fairman D., A true Markov model for sleep disturbance. PAGE.(2010).[more]
2009
Stringer F., Ploeger B., Scott G., Kawamura M. and Kupfer S., Pharmacokinetic and pharmacodynamic modeling of the novel oral direct factor Xa inhibitor TAK-442. ASCPT (2009).[more]
2009
Stringer F., Ploeger B., Jongh J.d., Scott G., Urquart R., Karim A. and Danhof M., Genotyped versus phenotyped dosing to account for UGT polymorphism of the novel PPAR agonist sipoglitazar PAGE.(2009)....[more]